Scientific Sessions 2025  /  Drugs and Hypertension – New Treatments Causing Hypertension and New Mechanisms for Treatment  /  Endothelin receptor antagonists
Logo

American Heart Association

  34
  0

Final ID:

Endothelin receptor antagonists

  • Blazek, Olivia  ( University of Chicago , Chicago , Illinois , United States )
  • Flack, John  ( SIU SCHOOL MEDICINE , Sprifield , Illinois , United States )
    • Author Disclosures:
    Olivia Blazek: DO NOT have relevant financial relationships | John Flack: DO have relevant financial relationships ; Researcher:Recor:Active (exists now) ; Other (please indicate in the box next to the company name):Teva; expert witness:Active (exists now) ; Researcher:Verve:Expected (by end of conference) ; Consultant:Astra Zeneca:Active (exists now) ; Researcher:Astra Zeneca:Active (exists now) ; Consultant:Idorsia:Active (exists now) ; Researcher:Idorsia:Active (exists now) ; Consultant:Casana:Active (exists now) ; Researcher:Mineralys:Active (exists now) ; Consultant:Mineralys:Active (exists now) ; Researcher:SonieVie:Active (exists now) ; Consultant:Recor:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Drugs and Hypertension – New Treatments Causing Hypertension and New Mechanisms for Treatment

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
RNA interfering agents

Desai Akshay, Webb David

Aldosterone synthase inhibitors

Laffin Luke, Weir Matthew

More abstracts from these authors:
Labile Hypertension: How Do I Tame This Rollercoaster?

Flack John, Ferdinand Keith

Not a "hypertensive urgency," change in terminology and outpatient management

Judd Eric, Flack John, Zachrison Kori

You have to be authorized to contact abstract author. Please, Login
Not Available